Bruch’s Membrane: A Key Consideration with Complement-Based Therapies for Age-Related Macular Degeneration
Year: 2023
Type: review
Abstract: The complement system is crucial for immune surveillance, providing the body's first line of defence against pathogens. However, an imbalance in its regulators can lead to inappropriate overactivation, resulting in diseases such as age-related macular degeneration (AMD), a leading cause of irreversible blindness globally affecting around 200 million people. Complement activation in AMD is believed to begin in the choriocapillaris, but it also plays a critical role in the subretinal and retinal pigment epithelium (RPE) spaces. Bruch's membrane (BrM) acts as a barrier between the retina/RPE and choroid, hindering complement protein diffusion. This impediment increases with age and AMD, leading to compartmentalisation of complement activation. In this review, we comprehensively examine the structure and function of BrM, including its age-related changes visible through in vivo imaging, and the consequences of complement dysfunction on AMD pathogenesis. We also explore the potential and limitations of various delivery routes (systemic, intravitreal, subretinal, and suprachoroidal) for safe and effective delivery of conventional and gene therapy-based complement inhibitors to treat AMD. Further research is needed to understand the diffusion of complement proteins across BrM and optimise therapeutic delivery to the retina.
Source: Journal of Clinical Medicine
DOI: 10.3390/jcm12082870
Language: English
Subfield: Ophthalmology
Field: Medicine
Domain: Health Sciences
Keywords: Bruch's membrane, age-related macular degeneration, complement system, complement activation, complement inhibitors, retinal pigment epithelium, choriocapillaris, gene therapy, drug delivery routes, intravitreal delivery, subretinal delivery, systemic drug delivery, in vivo imaging, AMD pathogenesis
Open Access status: gold
Estimated APC paid: $2,892
OpenAlex ID: W4365514215
